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1. Introduction 
Recently some Pros-analogs of Met/Leu’-enkephalin 
[l] containing a D-amino acid residue in position 2 
have been synthesized [2,3]. Of these analogs,(D-Met’, 
Pro’)-enkephalinamide (V, table 1) proved to be one 
of the most active analgesic of peptide nature [3]. 
According to more recent in vitro data, its effect is 
also influenced by Mn” [4]. 
The increased activity of analog V can be discussed 
both in terms of its stability to tissue peptidases and 
by assuming a conformation different from that 
proposed for Mets-enkephalin [5], with favourable 
transport and/or binding properties [6]. Finally the 
influence of metal ions on biological activity can be 
traced back to the formation of metal-peptide or 
peptide-metal-receptor complexes of proper stability 
under physiological conditions. 
Thus, in order to find a correlation between con- 
formation and biological activity, we performed CD 
investigations on Met-E and its Pros-analogs (table 1). 
Compounds III-V are Pro’-enkephalinamides 
containing D-amino acid residues in position 2. 
Compound II with Gly in the same position serves as 
an intermediate between enkephalin and the Pros- 
analogs containing D-amino acids. 
2. Experimental 
The syntheses of compounds I-V have been 
reported in [2,3]. CD measurements were performed 
at room temperature on a Jobin-Yvon-Roussell-Jouan 
model III dichrograph using spectral grade acetonitrile 
(AN), double-distilled water and analytical reagent 
grade salts. Concentration of the samples ranged 
between 0.25-0.35 mg/ml. Pathlength of the cell 
used was 0.01 cm. CD is expressed in mean residue 
ellipticity units (mo, deg. cm2/dmol). Due to the high 
noise level of the spectra, only the sign and shape of 
the CD curves have significance below 210 nm (cf. 
[7]). The pH of the aqueous solutions was adjusted 
by HCl or NaOH solutions. The free base form of 
compounds II-V was prepared using Amberlyst A-26 
anion exchange resin. CD titrations were performed 
in the ‘cell by adding I-10 ~1 1-5 M acetonitrile 
solution of the salts (NaC104, KC104, Ca(C104)2, 
Mn(C104)2) to the solution (0.7-l .O ml) of the pep- 
tide in AN. 
Table 1 
Structure and relative antinociceptive potency [ 31 of Met’-enkephalin and 
Pros-enkephalinamide analogs 
No. Compound Potency ratio on a molar basis 
(morphine = 1) 
Intravenously Centrally 
I H-Tyr-Gly-Gly-Phe-Met-OH (Met-E) 0 < 0.02 
II H-Tyr-Gly-Gly-Phe-Pro-NH, . HCl <0.02 < 0.02 
III H-Tyr-D-Ala-Gly-Phe-Pro-NH, . HCl 0.22 3.9 
IV H-Tyr-D-Nle-Gly-Phe-Pro-NH, . TFA 0.7 18.1 
V H-Tyr-D-Met-Gly-Phe-Pro-NH, . AcOH 5.9 78.5 
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3. Results 
CD extrema in the 270-200 nm region of Met-E 
and Pros-enkephalinamides II-V under different con- 
ditions are summarized in table 2. 
Analogs II-V in water show the same behaviour at 
pH <7 as Met-E itself (table 2, fig.1; cf. 171). At 
pH 11 .O, the shape of the spectra of compounds I-V 
is similar in the 270-210 nm region but differs below 
210 nm, where the ellipticity of the Gly’-analog (II) 
is negative, contrary to the positive m. values of 
Met-E and analogs III-V. 
CD spectra in AN strongly depend on whether or 
not the molecule is protonated. In the cationic form, 
analogs II-V show spectra which are very similar to 
that found in water at pH <7 (table 2). By contrast, 
the spectra of the free bases can be characterized by 
a negative xtremum in the 232-239 nm region, a 
shoulder or a weak positive band at -220 nm and by 
positive ellipticity values below 210 nm (see, e.g., 
fig. 1). On addition of 1 equiv. TFA to the solution of 
the free bases in AN, the spectra of the cationic forms 
is obtained again. 
Met-E in acetonitrile does not exhibit the same 
Fig.1. CD spectra of (D-Mets, Pro*)enkephalinamide (V) at 
4.6-5.2 X lo-’ M in water: pH 3 (11, pH 11 (2) and in 
~tonitrile:~A salt (31, free base (4). 
Table 2 
CD extrema of Met’-enkephalin and its analogs II-V in water and acetonitrile solution 
Compound h(rn@ x 10-3) 
PR 3 
In water 
pH 11 Protonated 
form 
In acetonitrile 
Free base Free base + Free base + 
2 equiv. Ca’+ 2 equiv. Mn*+ 
I 230’ 
221 (4.6) 
<205 (>4.7) 
II 
222 (3.6) 
<205 (>3.4) 
III 227c 
221 (5.6) 
<205 (>6.5) 
IV 227c 
222 (5.4) 
<205 06.6) 
V 
230c 
221 (4.5) 
<205 (>5.4) 
240 (0.5) 
217 (2.3) 
<205 (+) 
246 (0.2) 
228 (-0.5) 
218 (0.5) 
<215 (-) 
244 (1.2) 
219 (1.9) 
<205 (+) 
245 (0.9) 
220 (1.4) 
<205 (>2.0) 
243 (1.3) 
220 (1.9) 
<205 (>1.6) 
228 (6.1)a 
<205 (>4.6) 
245 (-0.15)a 
230c 
223 (4.65) 
<205 05.1) 
227 (5.15)a 
<205 (>3.9) 
244 (-0.35) 
222 (5.4) 
<205 (>3.8) 
244 (-0.3) 
230c 
222 (6.75) 
<205 (>4.6) 
228 (3.0)b 
207 (2.8) 
232 (-2.2)a 
218’ 
<205 (>1.6) 
239 (-0.85)a 
221 (2.3) 
<205 (>4.6) 
233 (-2.3) 
21gc 
<205 (>3.7) 
235 (-2.15) 
220 (0.5) 
<205 (>l.O) 
228 (3.1)b 
<205 (<-2.0) 
230Cga 
222 (3.5) 
22.5 (4.4)a 227 (2.3)a 
<210 (-) 209 (-1.95) 
230c 234c 
225 (3.8) 228 (2.4) 
<210 (<-1.3) <210 (c-2.4) 
230c 
222 (5.3) 
20gc 
230 (2.6) 
212 (-2.1) 
231 (1.85jb 
<20.5 (<-4.1) 
24gayC 
221 (1.9) 
213 (-0.3) 
<205 (>1.4) 
aWith 10% (v/v) HFIP added; bMeasured as sodium salt, with solvent as at a; CShoulder 
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characteristic spectral change on d,eprotonation with 
0.1 M aqueous NaOH as analogs II-V (fig.2). [The 
effect on CD spectra of the small quantities of water 
(4-6 .&/ml AN) can be neglected.] 
We also tried to deprotonate the cationic form of 
analogs II-V (see table 1, compound V was measured 
as trifluoroacetate salt) by adding 0.1 M aqueous 
NaOH to their AN solution in the cell. As indicated 
by the appearance of CD spectra characteristic to the 
free base form, complete deprotonation of the Gly’ 
and D-Ala’ analogs required l-l .5 equiv. NaOH, 
while in the case of the D-Met’ analog addition of 
-5 equiv. NaOH was needed. The most interesting 
result of our CD measurements is, however, that 
compound IV, the cfosest analog of the extremely 
potent (D-Met2, Pro’)~nkephalinamide, showed the 
same spectrum in AN both with and without addition 
of 15 equiv. NaOH. 
Finally, we measured CD spectra of Met-E and 
analogs II-V in water and AN solution in the presence 
Fig.2. CD spectra of Met*-enkephalin (I) at 5.5-6.7 X 1 Om4 M 
in water: pH 3 (1) and in acetonitrile containing 10% (v/v) 
hexafluoroisopropanol: TFA salt (2), sodium salt (3), sodium 
salt + 2 equiv. CafClO,), f4), sodium salt + 2 equiv. Mn(ClO& 
(51. 
of K”, Na+, Ca2+ and Mn 2+. Contrary to the results in 
[8], the small spectral changes obtained in water on 
addition of a large excess of salts, were found to be 
comparable to the high noise level of the spectra. So 
we continued our measurements in AN. Met-E was 
measured in the form of its sodium salt, analogs II-V 
as free bases. 
The CD spectrum of compounds I-V in AN is 
inff uenced by K’ only to a negli~ble extent. Na’ 
cause a deiinite spectral change, but only at higher 
salt concentrations (see, e.g., fig.3). By contrast, addi- 
tion of Ca2+ or Mn” perchlorates to the solution of 
analogs II-V in AN alters the spectrum very strongly 
(table 2, fig.3). 
The spectrum of the deprotonated form of Met-E 
in AN is influenced by CaZC and Mn” especially 
below 210 nm, where the second positive extremum 
disappears and the ellipticity values become negative 
in both cases (fig.2). 
4. Discussion 
CD spectra of Met-E in water and in the presence 
of Na+ and K’ were first reported in [8]. Its absorption 
and CD spectra were also measured in aqueous solu- 
Fig.3. CD spectra of (D-Me;*, ProS)enkephalinamide (free 
base) at 4.6 X 10T4 M in acetonitrile (1) and in the presence 
of NaClO, (IO equiv.) (2), Ca(ClO,), (2 equiv.) (3) and 
Mn(ClO,), (2 equiv.) (4). 
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tion as a function of temperature and pH, and in 
trifluoroethanol [7]. 
Our CD data concerning Met-E in water at pH <7 
(table 2) are in good agreement with those of the 
latter group. As in [7], we could not reproduce the 
fine structure of the spectrum of Met-E reported in 
[8]. More recent CD data on Leu’-enkephalin and its 
analogs also are qualitatively in agreement with our 
results [9]. 
Analogs II-V exhibit similar CD spectra in water 
at pH 3-5 and practically the same pH dependence, 
as Met-E itself. Consequently, neither the presence of 
the side chain of the D-amino acid residues of analogs 
III-V nor the replacement of methionine with nega- 
tively charged carboxylate group by amidated proline 
can play a dominant role in determining the chiroptical 
properties and the conformation of compounds II-V 
in water solution. 
Much more important is the degree of protonation 
of the terminal amino group of tyrosin, especially in 
the nonpolar solvent AN. Surprisingly, in spite of the 
considerable difference in the polarity of these 
solvents, the spectra of the cationic form of analogs 
II-V in water and AN solution show a great similarity 
(see, e.g., fig.1). It is very likely that the similarity of 
CD spectra is connected with the presence of a similar 
conformation in the two solvents. It may be well 
assumed that this conformation is fixed by relatively 
strong interactions between the positively charged 
alkylammonium group of tyrosine and the carbonyl 
oxygens of the peptide groups. The complexed 
cationic group is shielded from the solvent (or base) 
by the hydrophobic side chains of Tyr’, Phe4 and 
that of the D-amino acids in position 2. The extent of 
this shielding effect can be well detected by CD titra- 
tion in AN of the cationic form of analogs II-V with 
aqueous NaOH. This way the shielding of the alkyl- 
ammonium group has been found to decrease for 
analogs: IV >> V > III, II. [In agreement with the 
above assumption, protonation of the free base form 
of analog V in AN causes an expressed change in the 
whole 13C NMR spectrum (M. H., L. Radics (1979) 
preliminary data).] 
As for the biological data, the favourable transport 
properties going together with this ‘inner complexing’ 
can well explain the extremely good intravenous 
potency of (D-Met*, Pro5)-enkephalinamide. Analog IV 
with D-norleucine in position 2 seems to form the most 
stable complex. Its decreased in vivo activity may be 
due to the ‘excess’ stability of the complex leading to 
the lack of flexibility, as well. 
The formation of inner complexes can also be 
supported by the general complexing ability of these 
compounds. According to CD data (table 2, fIg.3), 
Met-E and in a more definite extent analogs II-V 
form complexes in AN with Ca*’ and MnZ+. The shape 
of CD curves of the Ca*’ complexes shows much 
similarity with the spectra of the parent compounds 
in protonated form. The Mn*‘complex exhibits some- 
what different CD spectra. 
CD titration performed on (D-Met*, Pro’)-enke- 
phalinamide shows that the binding of Ca*+ and Mn*+ 
is of a specific nature and the complexes of both ions 
have a 1: 1 stoichiometry, at least at higher salt:peptide 
molar ratios, By contrast, Na’ form complexes of much 
less stability with analog V (fig.4). 
The differences in the CD spectra of the Cap and 
Mn*’ complexes of Met-E and its analogs II-V are 
Fig.4. CD titration of (D-Met*, Pros)enkephalinamide in acetonitrile with Na+ (l), Mn* (2) and Ca* (3). 
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going parallel with the receptor binding experiments 
in [lo], according to which the inhibition by Met/ 
Leusenkephaline of [3H]naloxone binding is enhanced 
by Mn2+ but not Ca”. On the basis of our CD experi- 
ments, bivalent ions seem to form complexes with the 
opiate peptides under hydrophobic circumstances, while 
Na+ predominantly influence the receptor site confor- 
mation. At the same time, the formation of ‘inner’ and 
‘outer’ complexes of different stability by enkephalin 
and its analogs may also effect in vitro or in vivo bio- 
logical activity through the modification of transport 
properties of the parent molecules. 
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